NASP Highlights WellDyne Expertise

When treating chronic illness, prescribing should not be a guessing game. At the NASP 2022 Annual Meeting & Expo, WellDyne clinical leaders will lead an educational session on pharmacogenomic testing and precision medicine, covering the impact on healthcare outcomes, costs and implications for pharmacy benefit managers. The CPE-accredited session, Exploring the New Generation of Precision Medicine, will be led by Patty Taddei-Allen, VP, Clinical Programs and Services.

Exploring the New Generation of Precision Medicine
Presented by: Patty Taddei-Allen
NASP Annual Meeting & Expo
Wednesday, September 21, 10:15-11:15 am

With 1,200+ specialty pharmacy attendees, NASP offers more than 100 educational programs covering some of the most important topics and issues facing specialty pharmacy today. Patty will share how pharmacogenomic testing guides the best choice of drug and dosage for each individual – the first time, minimizing side effects and costly trial-and-error.

“PBMs have the expertise to educate and influence prescribers and patients, interpret test results, identify therapeutic opportunities and build effective benefit plans,” Patty explains. With a 33% projected investment increase in precision medicine from pharmaceutical leaders during the next five years, this area is primed for rapid growth.